EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Safety and efficacy of monoclonal antibody purified factor IX concentrate for management of spontaneous or trauma-induced bleeding and surgical prophylaxis in children with hemophilia B



Safety and efficacy of monoclonal antibody purified factor IX concentrate for management of spontaneous or trauma-induced bleeding and surgical prophylaxis in children with hemophilia B



Pediatric Research 35(4 PART 2): 163A




(PDF emailed within 1 workday: $29.90)

Accession: 033289064

Download citation: RISBibTeXText



Related references

Half-life, recovery and efficacy of continuous infusion monoclonal antibody purified factor IX in hemophilia B surgical, trauma, or severe spontaneous hemorrhage patients. Blood 90(10 SUPPL 1 PART 1): 35A, Nov 15, 1997

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thrombosis and Haemostasis 75(1): 30-35, 1996

Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage. Blood 98(11 Part 1): 532a, November 16, 2001

Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Haemophilia 3(4): 247-253, 1997

Compassionate treatment with a monoclonal antibody-purified factor IX concentrate in hemophilia B surgical patients who have experienced thrombotic complications with prothrombin complex concentrates. Blood 82(10 SUPPL 1): 154A, 1993

A post-marketing safety and efficacy assessment of a monoclonal antibody purified high-purity factor VIII concentrate. Haemophilia 2(1): 32-36, 1996

Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. American Journal of Hematology 51(2): 168-170, 1996

Safety of high doses of a monoclonal antibody-purified factor IX concentrate. American Journal of Hematology 49(1): 92-94, 1995

Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Seminars in Hematology 27(2 Suppl 2): 30-35, 1990

Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. American Journal of Hematology 49(1): 92-94, 1995

Home therapy from minor surgery and major bleeding using continuous infusion of monoclonal antibody purified factor VIII concentrate. Blood 86(10 SUPPL 1): 352A, 1995

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia 13(6): 697-700, 2007

Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients. Haemophilia 7(2): 146-153, 2001

Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs. Haemostasis 25(5): 229-236, 1995

Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. Journal of Pediatric Hematology/Oncology 21(1): 74-76, 1999